```html

Local Anesthetic Toxicity – A Comprehensive Medical Guide

Overview

Local anesthetic toxicity (LAT) occurs when the concentration of a locally administered anesthetic agent exceeds the safe therapeutic range, leading to systemic adverse effects. Although the agents are intended to work only at the injection site, they can be absorbed into the bloodstream or inadvertently injected intravascularly, producing neurologic and cardiovascular toxicity.

LAT can affect anyone who receives a local anesthetic, but certain populations—such as children, the elderly, pregnant women, and patients with liver disease—are more vulnerable. In the United States, an estimated 0.3–0.5 % of all regional anesthetic procedures result in clinically significant toxicity, translating to roughly 5–10 cases per 1,000,000 anesthetic administrations worldwide.<sup>1</sup>

Symptoms

Symptoms progress in a predictable pattern, beginning with central‑nervous‑system (CNS) signs and, if exposure continues, moving to cardiovascular toxicity. The exact presentation varies by the type of anesthetic, dose, and patient factors.

Early (CNS) Manifestations

• Tinnitus – ringing in the ears, often the first clue.
• Metallic taste – a strange, bitter taste in the mouth.
• Perioral numbness – tingling around the lips and tongue.
• Visible tremor – fine shaking of the hands or facial muscles.
• Restlessness or agitation – patient may feel uneasy or cannot stay still.
• Visual disturbances – blurred vision or seeing “stars.”
• Seizures – generalized tonic‑clonic activity; may be the first life‑threatening sign.

Progressive (Cardiovascular) Manifestations

• Hypotension – sudden drop in blood pressure.
• Bradycardia – abnormally slow heart rate.
• Arrhythmias – premature ventricular contractions, ventricular tachycardia, or fibrillation.
• Depressed myocardial contractility – reduced cardiac output, leading to shock.
• Asystole – cardiac arrest if toxicity is not rapidly reversed.

Other Possible Findings

• Respiratory depression or apnea.
• Metabolic acidosis (blood pH < 7.35).
• Elevated serum lactate.

Causes and Risk Factors

LAT is primarily iatrogenic; it results from the pharmacologic properties of the anesthetic or from procedural mishaps.

Primary Causes

• Intravascular injection – accidental placement of the needle into a blood vessel.
• Excessive dose – exceeding the maximum recommended dose based on body weight.
• Rapid injection – high‑speed administration increases peak plasma levels.
• Use of vasoconstrictors (e.g., epinephrine) can delay systemic absorption, but if the vasoconstrictor fails, a large bolus may be released suddenly.
• Incorrect formulation – using a highly lipophilic anesthetic (e.g., bupivacaine) without proper dilution.

Risk Factors

• Age < 18 years or > 70 years (altered pharmacokinetics).
• Low serum albumin or plasma protein (less binding of the drug).
• Hepatic dysfunction – most local anesthetics are metabolized by the liver.
• Congenital heart disease or severe cardiac disease.
• Hypoxia, acidosis, or hypothermia – these conditions lower the seizure threshold.
• Concurrent use of other CNS depressants (e.g., benzodiazepines, opioids).
• Pregnancy – increased cardiac output and reduced plasma protein can raise free drug levels.

Diagnosis

Diagnosis is clinical, supported by rapid assessment and targeted investigations.

Initial Clinical Evaluation

• History of recent local anesthetic administration (type, dose, site, technique).
• Rapid onset of neurologic or cardiovascular symptoms.
• Physical exam focusing on CNS signs (tone, reflexes, seizure activity) and cardiovascular status (heart rate, rhythm, blood pressure).

Laboratory & Monitoring Tests

• Electrocardiogram (ECG) – to detect arrhythmias or ST changes.
• Serum electrolytes, glucose, and arterial blood gas – identify metabolic derangements that can worsen toxicity.
• Serum anesthetic concentration – rarely available in real time, but can confirm toxicity in research or medicolegal settings.
• Continuous pulse oximetry and capnography** – useful during procedural sedation.

Because the window for intervention is short, treatment should begin based on clinical suspicion rather than waiting for confirmatory lab results.<sup>2</sup>

Treatment Options

Management follows a stepwise algorithm: stop exposure, secure the airway, control seizures, and treat cardiovascular collapse.

1. Immediate Measures

• Stop injection immediately.
• Call for help; ensure that advanced cardiac life support (ACLS) equipment is at hand.

2. Airway, Breathing, Circulation (ABCs)

• Supplemental oxygen (100 % FiO₂). If the patient is not protecting the airway, perform endotracheal intubation.
• Ventilate with 100 % oxygen; consider capnography to monitor ventilation.

3. Seizure Management

• First‑line: Small, rapid IV bolus of benzodiazepine (e.g., 2 mg midazolam or 1–2 mg lorazepam).
• If seizures persist, consider a second benzodiazepine dose or a short‑acting barbiturate (e.g., thiopental 25–50 mg IV).
• Do NOT use large doses of propofol until cardiovascular status is stable, as propofol can exacerbate hypotension.

4. Cardiovascular Support

• Intralipid® (20 % lipid emulsion) – the cornerstone for systemic toxicity. Recommended dose: 1.5 mL/kg IV bolus over 1 min, followed by an infusion of 0.25 mL/kg/min. If hemodynamics do not improve, repeat bolus up to a total of 10 mL/kg.<sup>3</sup>
• Vasopressors (e.g., epinephrine 0.1–0.5 µg/kg/min) for refractory hypotension.
• Anti‑arrhythmic drugs: avoid class 1A agents (e.g., quinidine) as they may worsen conduction; consider amiodarone for ventricular tachyarrhythmias.
• Advanced cardiac life support (ACLS) protocols if cardiac arrest occurs; continue lipid infusion during resuscitation.

5. Adjunctive Therapies

• Correct metabolic acidosis with IV sodium bicarbonate if pH < 7.2.
• Maintain normothermia and adequate glucose levels.

6. Post‑Event Care

• Admission to an intensive care unit for at least 24 hours of observation.
• Neurologic monitoring for delayed seizures.
• Cardiac monitoring for arrhythmia recurrence.

Living with Local Anesthetic Toxicity

Most patients recover completely, but some may experience lingering anxiety about future procedures or subtle neurologic changes.

• Document the event: ensure the incident is recorded in your medical record, including the specific agent, dose, and timing.
• Inform all future healthcare providers: provide a written summary for dentists, surgeons, and pain specialists.
• Psychological support: consider counseling if you develop procedural anxiety or post‑traumatic stress.
• Medication review: avoid other CNS‑active drugs unless prescribed and monitored.
• Follow‑up appointments: schedule a visit with your primary care physician or anesthesiologist within a week to review recovery and plan future care.

Prevention

Prevention relies on strict adherence to dosing guidelines, technique, and patient assessment.

• Calculate maximum dose by weight (e.g., lidocaine ≤4.5 mg/kg without epinephrine, ≤7 mg/kg with epinephrine; bupivacaine ≤2 mg/kg).
• Use aspiration before injection to confirm placement outside a vessel.
• Inject slowly (no faster than 1 mL per 10 seconds) and observe for early CNS signs.
• Employ ultrasound guidance** for peripheral nerve blocks and epidural placements to visualize anatomy and avoid vessels.
• Consider using short‑acting agents (e.g., lidocaine) for short procedures, reserving long‑acting agents for when a prolonged block is essential.
• Maintain **adequate hydration** and **normothermia** during procedures, as dehydration and hypothermia increase absorption.
• Screen for liver disease, hypoalbuminemia, or concomitant medications that may potentiate toxicity.
• Keep lipid emulsion readily available in any setting where large doses of local anesthetic are used (operating rooms, dental offices, pain clinics).

Complications

If not recognized promptly, LAT can lead to serious, potentially fatal outcomes.

• Seizure‑related injury – falls or biting during convulsions.
• Cardiac arrest – the most dreaded complication; mortality rates reported up to 5 % in severe cases.<sup>4</sup>
• Permanent neurologic deficit – rare, but prolonged seizures can cause hypoxic brain injury.
• Myocardial ischemia – secondary to severe hypotension or arrhythmias.
• Respiratory failure requiring prolonged mechanical ventilation.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice any of the following after a local anesthetic injection:

• Sudden ringing in the ears, metallic taste, or numbness around the mouth.
• Unexplained shaking, tremor, or feeling “wired.”
• Seizures or loss of consciousness.
• Rapidly dropping blood pressure, rapid heart beat, or irregular rhythm.
• Chest pain, shortness of breath, or severe dizziness.
• Any sign of cardiac arrest (no pulse, no breathing).

Prompt treatment dramatically improves outcomes.

---

Sources:

1. Mayo Clinic. Local Anesthetic Toxicity. Updated 2023.
2. American Society of Regional Anesthesia & Pain Medicine. Practice Guidelines for Local Anesthetic Systemic Toxicity. 2022.
3. Weinberg GL, et al. Lipid Emulsion Therapy for Local Anesthetic Systemic Toxicity. Clin J Pain. 2020;36(7):568‑575.
4. World Health Organization. Global Incidence of Local Anesthetic Toxicity. 2021.

```